Barinthus Biotherapeutics Overview
- Year Founded
-
2016
- Status
-
Public
- Employees
-
14
- Stock Symbol
-
2AB
- Investments
-
2
- Share Price
-
$0.70
- (As of Wednesday Closing)
Barinthus Biotherapeutics General Information
Description
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapeutic drug candidates for treating autoimmune and inflammatory diseases. The company is prioritizing the development of its proprietary SNAP-TI platform, designed to promote immune tolerance, with its lead candidate VTP-1000 targeting celiac disease. It is also developing VTP-300 for chronic hepatitis B using viral vector platform technologies, aimed at inducing disease-specific immune responses.
Contact Information
Website
www.barinthusbio.comCorporate Office
- 3rd Floor, 1 Ashley Road
- Cheshire
- Altrincham WA14 2DT
- England, United Kingdom
Corporate Office
- 3rd Floor, 1 Ashley Road
- Cheshire
- Altrincham WA14 2DT
- England, United Kingdom
Barinthus Biotherapeutics Stock Performance
As of 09-Sep-2026, Barinthus Biotherapeutics’s stock price is $0.70. Its current market cap is $30.2M with 40.8M shares.
(As of Wednesday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.70 | $0.71 | $0.52 - $1.51 | $30.2M | 40.8M | 20.34 | -$1.02 |
Barinthus Biotherapeutics Financials Summary
As of 30-Jun-2026, Barinthus Biotherapeutics has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | (27,631) | (35,015) | (42,833) | (11,793) |
| Revenue | 0 | 0 | 14,969 | 802 |
| EBITDA | (40,006) | (62,694) | (58,052) | (73,942) |
| Net Income | (41,767) | (66,428) | (61,074) | (73,347) |
| Total Assets | 81,893 | 98,169 | 160,327 | 214,506 |
| Total Debt | 10,295 | 11,281 | 12,007 | 12,976 |
Barinthus Biotherapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Barinthus Biotherapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Barinthus Biotherapeutics Comparisons
Industry
Financing
Details
Barinthus Biotherapeutics Competitors (124)
One of Barinthus Biotherapeutics’s 124 competitors is Protagonist Therapeutics, a Formerly VC-backed company based in Newark, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Protagonist Therapeutics | Formerly VC-backed | Newark, CA | ||||
| Kyverna | Formerly VC-backed | Emeryville, CA | ||||
| Annexon Biosciences | Formerly VC-backed | Brisbane, CA | ||||
| Xenetic Biosciences | Corporation | Framingham, MA | ||||
| Sarepta Therapeutics | Formerly VC-backed | Cambridge, MA |
Barinthus Biotherapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Barinthus Biotherapeutics Patents
Barinthus Biotherapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-11191825-B2 | Compositions and methods for vaccination against influenza | Active | 16-Sep-2016 | ||
| US-20190307877-A1 | Compositions and methods for vaccination against influenza | Active | 16-Sep-2016 | ||
| WO-2018053178-A1 | Compositions and methods for vaccination against influenza | Inactive | 16-Sep-2016 | A61K39/145 |
Barinthus Biotherapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Barinthus Biotherapeutics Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Barinthus Biotherapeutics Acquisitions (2)
Barinthus Biotherapeutics’s most recent deal was a Reverse Merger with Clywedog Therapeutics. The deal was made on 30-Sep-2025.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Clywedog Therapeutics | 30-Sep-2025 | Reverse Merger | Drug Delivery | ||
| Avidea Technologies | 10-Dec-2021 | Merger/Acquisition | Biotechnology |
Barinthus Biotherapeutics FAQs
-
When was Barinthus Biotherapeutics founded?
Barinthus Biotherapeutics was founded in 2016.
-
Where is Barinthus Biotherapeutics headquartered?
Barinthus Biotherapeutics is headquartered in Altrincham, United Kingdom.
-
What is the size of Barinthus Biotherapeutics?
Barinthus Biotherapeutics has 14 total employees.
-
What industry is Barinthus Biotherapeutics in?
Barinthus Biotherapeutics’s primary industry is Drug Discovery.
-
Is Barinthus Biotherapeutics a private or public company?
Barinthus Biotherapeutics is a Public company.
-
What is Barinthus Biotherapeutics’s stock symbol?
The ticker symbol for Barinthus Biotherapeutics is 2AB.
-
What is the current stock price of Barinthus Biotherapeutics?
As of 09-Sep-2026 the stock price of Barinthus Biotherapeutics is $0.70.
-
What is the current market cap of Barinthus Biotherapeutics?
The current market capitalization of Barinthus Biotherapeutics is $30.2M.
-
Who are Barinthus Biotherapeutics’s competitors?
Protagonist Therapeutics, Kyverna, Annexon Biosciences, Xenetic Biosciences, and Sarepta Therapeutics are some of the 124 competitors of Barinthus Biotherapeutics.
-
What is Barinthus Biotherapeutics’s annual earnings per share (EPS)?
Barinthus Biotherapeutics’s EPS for 12 months was -$1.02.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
